Regorafenib: a promising treatment for hepatocellular carcinoma

Lucia Cerrito, Francesca R. Ponziani, Matteo Garcovich, Annalisa Tortora, Brigida E. Annicchiarico, Maurizio Pompili, Massimo Siciliano, Antonio Gasbarrini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30% to 60%. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment. Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug. Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved.

Original languageEnglish
Pages (from-to)1941-1948
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Volume19
Issue number17
DOIs
Publication statusPublished - Nov 22 2018

Fingerprint

Hepatocellular Carcinoma
Pharmaceutical Preparations
Therapeutics
Survival
Expert Testimony
Cost-Benefit Analysis
Cause of Death
Neoplasms
sorafenib
regorafenib
Clinical Trials

Keywords

  • Hepatocellular carcinoma
  • regorafenib
  • second-line therapy
  • sorafenib
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Regorafenib : a promising treatment for hepatocellular carcinoma. / Cerrito, Lucia; Ponziani, Francesca R.; Garcovich, Matteo; Tortora, Annalisa; Annicchiarico, Brigida E.; Pompili, Maurizio; Siciliano, Massimo; Gasbarrini, Antonio.

In: Expert Opinion on Pharmacotherapy, Vol. 19, No. 17, 22.11.2018, p. 1941-1948.

Research output: Contribution to journalArticle

Cerrito, Lucia ; Ponziani, Francesca R. ; Garcovich, Matteo ; Tortora, Annalisa ; Annicchiarico, Brigida E. ; Pompili, Maurizio ; Siciliano, Massimo ; Gasbarrini, Antonio. / Regorafenib : a promising treatment for hepatocellular carcinoma. In: Expert Opinion on Pharmacotherapy. 2018 ; Vol. 19, No. 17. pp. 1941-1948.
@article{66d4b09ca16140879bd60ab2d15b5c4b,
title = "Regorafenib: a promising treatment for hepatocellular carcinoma",
abstract = "Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30{\%} to 60{\%}. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment. Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug. Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved.",
keywords = "Hepatocellular carcinoma, regorafenib, second-line therapy, sorafenib, tyrosine kinase inhibitor",
author = "Lucia Cerrito and Ponziani, {Francesca R.} and Matteo Garcovich and Annalisa Tortora and Annicchiarico, {Brigida E.} and Maurizio Pompili and Massimo Siciliano and Antonio Gasbarrini",
year = "2018",
month = "11",
day = "22",
doi = "10.1080/14656566.2018.1534956",
language = "English",
volume = "19",
pages = "1941--1948",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "17",

}

TY - JOUR

T1 - Regorafenib

T2 - a promising treatment for hepatocellular carcinoma

AU - Cerrito, Lucia

AU - Ponziani, Francesca R.

AU - Garcovich, Matteo

AU - Tortora, Annalisa

AU - Annicchiarico, Brigida E.

AU - Pompili, Maurizio

AU - Siciliano, Massimo

AU - Gasbarrini, Antonio

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30% to 60%. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment. Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug. Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved.

AB - Introduction: Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors with 854,000 new cases per year and represents the second most frequent cause of cancer-death. Despite surveillance, the number of patients that are diagnosed at a stage in which they are eligible for curative treatments ranges from 30% to 60%. Advanced HCC (BCLC-C) is characterized by a median survival of 6 months. Sorafenib, the first systemic drug proven to be effective in prolonging survival of unresectable HCC, was approved by the FDA in 2007 but no second-line treatment was available for a decade for patients progressing on sorafenib. Finally, in 2016, the RESORCE trial demonstrated regorafenib as an effective second-line treatment. Areas covered: In this manuscript, the authors review the principal preclinical and clinical trials on regorafenib used in the treatment of unresectable HCC patients progressing on sorafenib and highlight both the advantages and the limitations of this drug. Expert opinion: Regorafenib is the only second-line treatment available for patients progressing on sorafenib. Despite its promising clinical application, many doubts still remain, necessitating further investigation to explore the tolerability of this drug in Child-Pugh B and sorafenib-intolerant patients, while its scarce cost-effectiveness must also be improved.

KW - Hepatocellular carcinoma

KW - regorafenib

KW - second-line therapy

KW - sorafenib

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85055544692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055544692&partnerID=8YFLogxK

U2 - 10.1080/14656566.2018.1534956

DO - 10.1080/14656566.2018.1534956

M3 - Article

AN - SCOPUS:85055544692

VL - 19

SP - 1941

EP - 1948

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 17

ER -